论文部分内容阅读
<正>Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy.However,to date,there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patient